XML 27 R15.htm IDEA: XBRL DOCUMENT
v3.23.3

Intellectual Property, net | 12 Months Ended
--- | ---
Aug. 31, 2023
Intellectual Property, net |
Intellectual Property | 9. Intellectual Property, net The following is a list of capitalized US patents held by the Company.
Issued Patent # | Patent Certificate Grant Date | Patent Family
US 9,474,725 B1 | 10/25/2016 | #1 Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof
US 9,839,612 B2 | 12/12/2017
US 9,972,680 B2 | 05/15/2018
US 9,974,739 B2 | 05/22/2018
US 10,084,044 B2 | 09/25/2018
US 10,103,225 B2 | 10/16/2018
US 10,381,440 | 08/13/2019
US 10,374,036 | 08/06/2019
US 10,756,180 | 08/25/2020
US 11,311,559 | 04/26/2022 | #18 Compositions and Methods for Enhanced Delivery of Antiviral Agents
US 11,700,875 | 07/18/2023 | #20 Compositions and Methods for Sublingual Delivery of Nicotine
US 11,666,544 | 06/06/2023 | #21 Compositions and Methods for Treating Hypertension
US 11,666,543 | 06/06/2023
A continuity schedule for capitalized patents is presented below:
|  | August 31, |  |  | August 31, |
|  | 2023 |  |  | 2022 |
Balance – beginning |  | $ | 488,462 |  |  | $ | 364,623 |
Addition |  |  | 135,862 |  |  |  | 131,448 |
Impairment |  |  | (106,761 | ) |  |  | - |
Amortization |  |  | (54,938 | ) |  |  | (7,609 | )
Balance – ending |  | $ | 462,625 |  |  | $ | 488,462 |
At August 31, 2023 the Company has capitalized a total of $462,625 of patents. Included in the capitalized costs is $457,445 of costs associated with patents and licenses that have been filed. Also included in the capitalized costs is $5,180 of costs associated with provisional patents and pending applications which have not yet been filed. The Company evaluated its patent portfolio and determined that certain pending applications had been abandoned or would not be pursued. As such, during the year ended August 31, 2023, the Company recognized an impairment loss of $106,761 (2022 - $Nil) related to those abandoned applications. The Company recognized $54,938 of amortization expense related to patents and licenses in the year ended August 31, 2023 (2022 - $7,609).

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350-30/tableOfContent + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration